Bruker (NASDAQ:BRKR) Shares Up 9.2% – Time to Buy?

Bruker Corporation (NASDAQ:BRKR) shares traded up 9.2% on Thursday . The company traded as high as $53.22 and last traded at $53.1010. 1,276,187 shares changed hands during trading, a decline of 45% from the average session volume of 2,308,142 shares. The stock had previously closed at $48.62.

Analyst Ratings Changes

Several brokerages have recently commented on BRKR. The Goldman Sachs Group decreased their price objective on shares of Bruker from $40.00 to $35.00 and set a “sell” rating on the stock in a report on Friday, February 13th. Citigroup boosted their target price on Bruker from $40.00 to $44.00 and gave the company a “neutral” rating in a research report on Thursday, May 7th. Jefferies Financial Group set a $50.00 price target on Bruker in a research note on Thursday, February 12th. Weiss Ratings lowered Bruker from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. Finally, UBS Group lifted their price objective on Bruker from $40.00 to $45.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Bruker currently has an average rating of “Hold” and a consensus target price of $50.54.

Bruker Trading Up 8.3%

The company has a debt-to-equity ratio of 0.67, a current ratio of 1.55 and a quick ratio of 0.72. The firm has a market cap of $8.96 billion, a PE ratio of -245.38, a price-to-earnings-growth ratio of 3.26 and a beta of 1.12. The company’s 50 day moving average price is $40.14 and its 200 day moving average price is $42.85.

Bruker (NASDAQ:BRKR) last released its earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. Bruker had a negative net margin of 0.65% and a positive return on equity of 11.60%. The company had revenue of $823.40 million for the quarter, compared to analyst estimates of $795.62 million. During the same period in the prior year, the business earned $0.47 EPS. The firm’s quarterly revenue was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, analysts forecast that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 7th. Investors of record on Monday, June 22nd will be issued a $0.05 dividend. The ex-dividend date is Monday, June 22nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. Bruker’s dividend payout ratio (DPR) is -83.33%.

Insider Buying and Selling

In related news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total transaction of $79,800.00. Following the completion of the transaction, the vice president directly owned 128,443 shares of the company’s stock, valued at $5,124,875.70. The trade was a 1.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 27.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Bruker

Several hedge funds and other institutional investors have recently made changes to their positions in BRKR. Los Angeles Capital Management LLC acquired a new stake in Bruker in the fourth quarter valued at approximately $26,000. Parallel Advisors LLC grew its holdings in Bruker by 121.0% during the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after acquiring an additional 479 shares in the last quarter. Allworth Financial LP increased its position in shares of Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 257 shares during the last quarter. Essential Partners LLC purchased a new stake in shares of Bruker in the 1st quarter valued at approximately $36,000. Finally, Summit Securities Group LLC acquired a new stake in shares of Bruker in the 4th quarter valued at $50,000. Hedge funds and other institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.